Deals
Deals dated after 30 September 2026 are still being collected.
Columns
21 of 21 deals
| Advisers | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2026 | GoPro | – | – | Merger | Legal adviser to GoPro (target) | Announced | 285.0 | Consumer Electronics+2 | Houlihan Lokey (sell-side) | Starman Optical and GoPro merger |
| Aug 2026 | FORT Robotics | – | Newbury Street II Acquisition Corp | Merger | Legal adviser to FORT Robotics (target) | Announced | – | Robotics+3 | BTIG (buy-side)Ellenoff Grossman & Schole (buy-side)Evercore (sell-side)FINN PartnersCollected StrategiesLoeb & Loeb (lead manager) | Newbury Street II Acquisition Corp and FORT Robotics merger |
| Aug 2026 | Wisk Aero | The Boeing Company | Archer Aviation | Asset sale | Legal adviser to Archer Aviation (acquirer) | Pending | – | Defence & Aerospace+3 | Moelis & Company (buy-side)J.P. Morgan (sell-side)Mayer Brown (sell-side) | Archer Aviation acquisition of Wisk Aero |
| Aug 2026 | VitalConnect | – | iRhythm Holdings | Acquisition | Legal adviser to iRhythm Holdings (acquirer) | Announced | 287.5 | Medtech | Goldman Sachs (buy-side) | iRhythm Holdings acquisition of VitalConnect |
| Aug 2026 | Attovia Therapeutics | – | – | IPO | Legal adviser to the issuer | Listed | 289.0 | Biotech+1 | Morgan Stanley (lead manager)Leerink Partners (lead manager)Citi (lead manager)RBC Capital Markets (lead manager)LifeSci Capital (lead manager)Cooley (lead manager) | Attovia Therapeutics IPO |
| Jul 2026 | Anyscale | – | Nscale | Acquisition | Legal adviser to Anyscale (target) | Pending | – | AI+1 | Latham & Watkins (buy-side)Goldman Sachs (buy-side)Morgan Stanley (buy-side)Qatalyst Partners (sell-side) | Nscale acquisition of Anyscale |
| Jul 2026 | Synlogic | – | – | Merger | Legal adviser to Caldera Therapeutics (acquirer) | Announced | – | Biotech+1 | Lucid Capital Markets (sell-side)Mintz (sell-side) | Caldera Therapeutics and Synlogic merger |
| Jul 2026 | Scribe Therapeutics | – | – | IPO | Legal adviser to the issuer | Listed | 128.7 | Biotech+1 | Leerink Partners (lead manager)Goldman Sachs (lead manager)Guggenheim Securities (lead manager)Wells Fargo Securities (lead manager)Latham & Watkins (lead manager) | Scribe Therapeutics IPO |
| Jul 2026 | Nauto | – | – | Merger | Legal adviser to Nauto | Announced | – | AI+2 | BofA Securities | Nexar and Nauto merger |
| Jun 2026 | Remix Therapeutics | – | Passage Bio | Merger | Legal adviser to Passage Bio (acquirer) | Pending | – | Biotech+2 | Latham & Watkins (sell-side)Wedbush SecuritiesRBC Capital MarketsCanaccord Genuity | Passage Bio and Remix Therapeutics merger |
| Jun 2026 | Vega Therapeutics | Star Therapeutics | Incyte | Acquisition | Legal adviser to Star Therapeutics (seller) | Completed | 1,250.0 | Biotech+2 | Lazard (buy-side)Goodwin (buy-side)Evercore (sell-side)Morgan Stanley (sell-side) | Incyte acquisition of Vega Therapeutics |
| Jun 2026 | Standard BioTools | – | – | Merger | Legal adviser to Treeline Biosciences (target) | Pending | 460.0 | Biotech+2 | Centerview Partners (buy-side)Freshfields (buy-side)Richards, Layton & Finger (buy-side)UBS (buy-side)Wedbush Securities (sell-side) | Treeline Biosciences and Standard BioTools merger |
| May 2026 | Tonkean | – | Coupa | Acquisition | Legal adviser to Tonkean (target) | Announced | – | Enterprise Software+2 | Kirkland & Ellis (buy-side)Cascadia Capital (sell-side) | Coupa acquisition of Tonkean |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Legal adviser to KalVista (target) | Completed | 1,900.0 | Pharma+2 | Lazard (buy-side)Ropes & Gray (buy-side)Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Jefferies (sell-side) | Chiesi Group acquisition of KalVista Pharmaceuticals |
| Apr 2026 | Naveris | – | CareDx | Acquisition | Legal adviser to CareDx (acquirer) | Announced | 160.0 | Diagnostics+1 | Goldman Sachs (buy-side)J.P. Morgan (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side) | CareDx acquisition of Naveris |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Legal adviser to Day One (target) | Pending | 2,500.0 | Biotech+2 | Goldman Sachs (buy-side)Baker McKenzie (buy-side)Centerview Partners (sell-side)Innisfree M&A (buy-side) | Servier acquisition of Day One Biopharmaceuticals |
| Feb 2026 | Pixel Flow! development studio | – | Scopely | Acquisition | Legal adviser to Pixel Flow! development studio (target) | Announced | – | Video games | Skadden, Arps, Slate, Meagher & Flom (buy-side)Hergüner Bilgen Üçer (buy-side) | Scopely acquisition of Pixel Flow! development studio |
| Jan 2026 | BitGo Holdings | – | – | IPO | Legal adviser to the issuer | Announced | 212.8 | Crypto & Web3 | Goldman Sachs (lead manager)Citi (lead manager)Deutsche Bank (lead manager)Mizuho Securities (lead manager)Wells Fargo Securities (lead manager)Keefe, Bruyette & Woods (lead manager)Canaccord Genuity (lead manager)Cantor Fitzgerald (lead manager)Clear Street (lead manager)Compass Point Research & Trading (lead manager)Craig-Hallum (lead manager)Rosenblatt Securities (lead manager)Wedbush Securities (lead manager)SoFi Securities (lead manager)Cravath, Swaine & Moore (lead manager)Whalen LLP (issuer) | BitGo Holdings IPO |
| Jan 2026 | Mersana Therapeutics | – | Day One Biopharmaceuticals | Acquisition | Legal adviser to Day One (acquirer) | Completed | – | Biotech+2 | Gordon Dyal & Co. (buy-side)TD Securities (sell-side)WilmerHale (sell-side) | Day One Biopharmaceuticals acquisition of Mersana Therapeutics |
| Sep 2024 | Smartsheet | – | Blackstone | Acquisition | Legal adviser to Smartsheet (target) | Completed | 8,400.0 | Enterprise Software+1 | Qatalyst Partners (sell-side)Goldman Sachs (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)Simpson Thacher & Bartlett (buy-side) | Blackstone acquisition of Smartsheet |
| Apr 2024 | Model N | – | Vista Equity Partners | Acquisition | Legal adviser to Model N (target) | Completed | 1,250.0 | Vertical SaaS+1 | Jefferies (sell-side)Kirkland & Ellis (buy-side)William Blair (buy-side) | Vista Equity Partners acquisition of Model N |
Activity
By announcement date; raisings and IPOs by their own date.
Sector of the business bought or funded.
Disclosed value in US dollars.
Most often across the table
- Goldman Sachs
3 dealsCompare - Kirkland & Ellis
3 dealsCompare - Lazard
2 dealsCompare - Morgan Stanley
2 dealsCompare - J.P. Morgan
2 dealsCompare - Skadden, Arps, Slate, Meagher & Flom
2 dealsCompare - Latham & Watkins
2 dealsCompare - Goodwin
1 dealCompare
Firms advising the other side of the same deals.
Repeat clients
- Day One2 deals